ChinaBio Today -- Wuxi MTLH Biotechnology Co., a company founded in December 2007, has sold the China rights for its lead molecule, an anti-cancer drug, to Shanghai The First Biochemical Pharmaceutical Co. Ltd., a subsidiary of Shanghai Pharmaceutical Group. MTLH-001 is a peptide PDGFR antagonist in pre-clinical development. SBPC will co-develop the product with MTLH according to FDA standards, helping MTLH to launch the drug globally. More details...
